Back to list
huifer

patent-search

by huifer

Drug Discovery Intelligence plugin for Claude Code. AI-powered target validation, competitive intelligence, literature analysis & clinical trials insights. Integrates Open Targets, ChEMBL, PubMed & 5+ databases.

2🍴 0📅 Jan 20, 2026

SKILL.md


name: patent-search description: | Search and analyze patents including FTO (Freedom to Operate) analysis, patent landscape mapping, and competitive IP intelligence.

Keywords: patent, FTO, freedom to operate, IP, intellectual property category: Patent Analysis tags: [patent, fto, ip, landscape, claims] version: 1.0.0 author: Drug Discovery Team dependencies:

  • uspto-database
  • epo-database
  • wipo-database

Patent Search Skill

Comprehensive patent analysis for drug discovery and IP intelligence.

Quick Start

/patent EGFR inhibitor
/fto "quinazoline EGFR kinase"
/patent-map KRAS G12C
Analyze patent landscape for osimertinib

What's Included

SectionDescriptionData Source
Patent SearchFind relevant patentsUSPTO, EPO, WIPO
Patent DetailsClaims, assignees, priorityPatent databases
FTO AnalysisFreedom to operate assessmentClaims analysis
Landscape MapPatent clustering and gapsAggregated
ExpirationPatent expiry datesPatent databases
Family AnalysisPatent family membersGlobal Dossier

Output Structure

# Patent Analysis: EGFR Inhibitors

## Executive Summary
**Total Patents**: 3,247 EGFR inhibitor patents found
**Key Patent Families**: 89 unique families
**FTO Risk**: High - crowded landscape with broad claims

## Patent Landscape
| Time Period | Patents | Growth |
|-------------|---------|--------|
| 1990-1999 | 234 | Baseline |
| 2000-2009 | 892 | +281% |
| 2010-2019 | 1,456 | +63% |
| 2020-2024 | 665 | Declining |

## Key Patent Families

### US5747498 (Erlotinib)
| Field | Value |
|-------|-------|
| Assignee | OSI Pharmaceuticals |
| Priority Date | 1994-04-15 |
| Grant Date | 1998-05-05 |
| Expiry | 2018 (expired) |
| Claims | 47 claims |
| Scope | Quinazoline EGFR inhibitors |

### US8017621 (Gefitinib)
| Field | Value |
|-------|-------|
| Assignee | AstraZeneca |
| Priority Date | 1992-03-06 |
| Expiry | 2014 (expired) |
| Scope | Broad EGFR TKI claims |

## FTO Analysis

### High-Risk Patents
| Patent | Risk | Reason |
|--------|------|--------|
| US8772358 | ⚠️ High | 3rd-gen TKI, C797S active |
| US10363010 | ⚠️ High | Broad mutant-selective claims |
| US10588034 | ⚠️ High | Combination therapy claims |

### White Space
| Area | Opportunity | Rationale |
|------|-------------|----------|
| 4th-gen TKI | Low IP pressure | C797S+S1278 niche |
| Allosteric sites | Emerging | Fewer existing claims |
| Bispecific formats | Moderate | Combination IP possible |

## Patent Family Analysis
**Example: Osimertinib (AZD9291)**

| Jurisdiction | Patent | Status | Expiry |
|-------------|--------|--------|--------|
| US | US8772358 | Expired | 2033 |
| EP | EP2378967 | Granted | 2033 |
| JP | JP5958971 | Granted | 2033 |
| CN | CN102822420 | Granted | 2033 |

## Claim Analysis
**US8772358 Claim 1 (Representative):**

A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a proliferative disease mediated by EGFR having the T790M mutation...


**Breadth:** Broad - covers mutant-selective EGFR inhibitors
**Enforceability:** High - well-defined structure
**Workaround:** Difficult - covers core scaffold

## Competitive IP Map
| Company | Patent Families | Core Focus |
|----------|-----------------|-------------|
| AstraZeneca | 12 | 3rd-gen TKI, combinations |
| Johnson & Johnson | 8 | Bispecific antibodies |
| Daiichi Sankyo | 6 | ADC conjugates |
| Blueprint Medicines | 4 | 4th-gen TKI |
| Yuhan/Roche | 3 | Lazertinib combinations |

Examples

/patent EGFR quinazoline
/patent-search "KRAS G12C inhibitor"
Find all patents for sotorasib

FTO Analysis

/fto "EGFR TKI scaffold"
/fto-analysis compound.smi
Can I make this compound without infringement?

Landscape Mapping

/patent-map KRAS inhibitors
Map patent landscape for 4th-gen EGFR
Analyze IP gaps in PROTAC EGFR degraders

Patent Family

/patent US8772358 --family
/patent WO2010130291 --global
Show all related patents for osimertinib

Running Scripts

# Search patents by keyword
python scripts/patent_search.py "EGFR inhibitor" --output patents.json

# FTO analysis
python scripts/patent_search.py --fto "quinazoline scaffold" --claims

# Patent family lookup
python scripts/patent_search.py --family US8772358

# Landscape mapping
python scripts/patent_search.py --landscape "KRAS G12C" --cluster

# Expiration analysis
python scripts/patent_search.py --expiry "EGFR TKI" --sort-by-date

Requirements

pip install requests pandas lxml

Additional Resources

Best Practices

  1. Start broad: Cast wide net, then filter
  2. Check families: Patents span multiple jurisdictions
  3. Read claims: Scope determined by claims, not abstract
  4. Check expiry: Many drug patents expired
  5. Consider licenses: Blocked ≠ impossible (licensing possible)

Common Pitfalls

PitfallSolution
Narrow searchUse multiple terms/synonyms
Ignoring familiesCheck global coverage
Misreading claimsClaims define scope, not title
Overlooked continuationsCheck continuation-in-part (CIP)
Publication vs. grantCheck granted patent status

Score

Total Score

65/100

Based on repository quality metrics

SKILL.md

SKILL.mdファイルが含まれている

+20
LICENSE

ライセンスが設定されている

0/10
説明文

100文字以上の説明がある

+10
人気

GitHub Stars 100以上

0/15
最近の活動

1ヶ月以内に更新

+10
フォーク

10回以上フォークされている

0/5
Issue管理

オープンIssueが50未満

+5
言語

プログラミング言語が設定されている

+5
タグ

1つ以上のタグが設定されている

+5

Reviews

💬

Reviews coming soon